Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.709
Peer-review started: July 31, 2021
First decision: October 22, 2021
Revised: November 2, 2021
Accepted: December 10, 2021
Article in press: December 10, 2021
Published online: January 14, 2022
Processing time: 164 Days and 12.6 Hours
Diffuse large B-cell lymphoma, which accounts for about approximately 30% to 40% of non-Hodgkin's lymphomas, is the most common type and is a class of aggressive B-cell lymphomas. However, diffuse large B-cell lymphomas primary to the adrenal gland are rare.
A 73-year-old man was admitted with abdominal pain and fatigue. After admission, enhanced adrenal computed tomography indicated irregular masses on both adrenal glands, with the larger one on the left side, approximately 8.0 cm × 4.3 cm in size. The boundary was irregular, and surrounding tissues were compressed. No obvious enhancement was observed in the arterial phase. Resection of the left adrenal gland was performed. Pathological diagnosis revealed diffuse large B-cell lymphoma. After surgery, the patient received R-CHOP immunochemotherapy. During the fourth immunochemotherapy, patient condition deteriorated, and he eventually died of respiratory failure.
R-CHOP is the conventional immunochemotherapy for primary adrenal diffuse large B-cell lymphoma. Surgery is mainly used to diagnose the disease. Hence, the ideal treatment plan remains to be confirmed.
Core Tip: Primary adrenal diffuse large B-cell lymphoma is a rare disease with no consistent treatment standards. The R-CHOP regimen is the conventional immunochemotherapy regimen for this disease. We report a case of surgery combined with immunochemotherapy; however, immunochemotherapy was ineffective and the patient eventually died of respiratory failure. Therefore, the optimal treatment of primary adrenal diffuse large B-cell lymphoma remains to be further explored.